Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

SHE:002653 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	4,242	3,693	3,335	2,998	2,765	3,328
Other Revenue	28.6	28.6	19.94	17.03	8.46	2.08
Revenue	4,270	3,721	3,355	3,015	2,773	3,330
Revenue Growth (YoY)	14.72%	10.92%	11.27%	8.72%	-16.71%	-15.43%
Cost of Revenue	1,168	1,062	971.25	925.27	946.88	1,068
Gross Profit	3,102	2,660	2,384	2,090	1,826	2,262
Selling, General & Admin	2,006	1,763	1,521	1,464	1,331	1,586
Research & Development	788.56	624.13	516.67	447.87	431.4	405.53
Other Operating Expenses	83.35	8.6	13.98	35.82	26.28	42.69
Operating Expenses	2,879	2,398	2,052	1,948	1,789	2,034
Operating Income	222.86	262.03	331.58	141.57	37.6	228.35
Interest Expense	-33.85	-37.84	-42.28	-50.91	-27.16	-27.29
Interest & Investment Income	16.96	140.71	19.33	235.41	426.35	301.58
Currency Exchange Gain (Loss)	0.76	0.76	-0.06	0.97	-0.17	-2.43
Other Non Operating Income (Expenses)	-1.29	-1.81	-0.63	1.13	-1.1	-7.1
EBT Excluding Unusual Items	205.43	363.84	307.93	328.16	435.52	493.1
Gain (Loss) on Sale of Investments	-13.47	0.08	-60.47	-	-	-
Gain (Loss) on Sale of Assets	5.93	31.1	-0.28	-0	-0.13	0.33
Asset Writedown	-33.82	-83.19	-13.02	-0.84	-0.62	-18.79
Other Unusual Items	155.72	151.12	68.37	39.3	75.97	214.8
Pretax Income	319.79	462.95	302.52	366.61	510.74	689.45
Income Tax Expense	10.32	-3.25	6.96	-25.1	-6.84	88.25
Earnings From Continuing Operations	309.47	466.2	295.56	391.71	517.58	601.2
Minority Interest in Earnings	-0.53	-70.74	-0.45	-114.64	-172.52	35.42
Net Income	308.94	395.46	295.11	277.07	345.06	636.62
Net Income to Common	308.94	395.46	295.11	277.07	345.06	636.62
Net Income Growth	-35.12%	34.00%	6.51%	-19.70%	-45.80%	28.90%
Shares Outstanding (Basic)	1,130	1,130	1,093	1,066	1,078	1,079
Shares Outstanding (Diluted)	1,130	1,130	1,093	1,066	1,078	1,079
Shares Change (YoY)	2.50%	3.37%	2.57%	-1.17%	-0.07%	0.50%
EPS (Basic)	0.27	0.35	0.27	0.26	0.32	0.59
EPS (Diluted)	0.27	0.35	0.27	0.26	0.32	0.59
EPS Growth	-36.71%	29.63%	3.85%	-18.75%	-45.76%	28.26%
Free Cash Flow	227.27	1.39	58.57	-605.62	-667.14	-395.51
Free Cash Flow Per Share	0.20	0.00	0.05	-0.57	-0.62	-0.37
Dividend Per Share	0.135	0.415	0.200	-	0.185	0.372
Dividend Growth	-71.88%	107.50%	-	-	-50.22%	304.35%
Gross Margin	72.65%	71.47%	71.05%	69.31%	65.86%	67.93%
Operating Margin	5.22%	7.04%	9.88%	4.70%	1.36%	6.86%
Profit Margin	7.23%	10.63%	8.80%	9.19%	12.44%	19.12%
Free Cash Flow Margin	5.32%	0.04%	1.75%	-20.09%	-24.06%	-11.88%
EBITDA	476.91	498.35	544.25	317.33	183.93	332.93
EBITDA Margin	11.17%	13.39%	16.22%	10.52%	6.63%	10.00%
D&A For EBITDA	254.06	236.32	212.67	175.76	146.33	104.59
EBIT	222.86	262.03	331.58	141.57	37.6	228.35
EBIT Margin	5.22%	7.04%	9.88%	4.70%	1.36%	6.86%
Effective Tax Rate	3.23%	-	2.30%	-	-	12.80%
Revenue as Reported	4,270	3,721	3,355	3,015	2,773	3,330
Advertising Expenses	-	-	-	-	3.74	6.74

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.